文献速递神经肿瘤

患者来源胶质瘤类器官联合差分离子迁移谱实时识别IDH突变、1p/19q共缺失及CDKN2A/B纯合缺失

Patient-derived glioma organoids real time identification of IDH mutation, 1p/19q-codeletion and CDKN2A/B homozygous deletion with differential ion mobility spectrometry.
PubMed 文献 · J Neurooncol · 2024-11-23

研究前瞻性纳入12例胶质瘤患者(6例IDH突变型、6例IDH野生型),体外生成患者来源胶质瘤类器官(PGOs),用差分离子迁移谱(DMS)分析320份PGOs光谱并以线性判别分析(LDA)分类。IDH突变与野生型分类准确率90%(灵敏度91%、特异度89%),IDH突变型内1p/19q共缺失分类准确率98%(灵敏度93%、特异度99%),CDKN2A/B纯合缺失分类准确率86%(灵敏度63%、特异度93%)。

要点

  • DMS联合LDA对PGOs的IDH突变分类准确率90%(灵敏度91%、特异度89%)。
  • IDH突变型PGOs中1p/19q共缺失分类准确率98%(灵敏度93%、特异度99%)。
  • CDKN2A/B纯合缺失分类准确率86%(灵敏度63%、特异度93%)。

核心结论

  • DMS在体外培养的PGOs样本中可区分IDH突变型PGOs,该适用性得到验证。
  • 关于1p/19q共缺失PGOs和CDKN2A/B缺失PGOs识别的初步结果支持在前瞻性术中胶质瘤患者队列中检测。
  • 结果提示该样本分类方案与实时术中手术指导兼容。

研究设计与样本

  • 前瞻性招募12例胶质瘤患者,其中6例IDH突变型、6例IDH野生型肿瘤,体外生成PGOs。
  • 共分析320份PGOs的DMS光谱,采用基于线性判别分析(LDA)的分类器算法。

主要发现

  • LDA模型在IDH突变型与IDH野生型PGOs间的分类准确率为90%(灵敏度91%、特异度89%)。
  • IDH突变型PGOs内1p/19q共缺失分类准确率达98%(灵敏度93%、特异度99%)。
  • CDKN2A/B纯合缺失状态分类准确率为86%(灵敏度63%、特异度93%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Extent of brain tumor resection continues to be one of the central decisions taken during standard of care in glioma patients. Here, we aimed to evaluate the most essential molecular factors, such as IDH (isocitrate dehydrogenase) mutation in gliomas classification with patient-derived glioma organoids (PGOs) using differential mobility spectrometry (DMS). METHODS: we prospectively recruited 12 glioma patients, 6 IDH-mutated and 6 IDH wild-type tumors, from which PGOs were generated ex-vivo. Altogether, 320 PGOs DMS spectra were analyzed with a classifier algorithm based on linear discriminant analysis (LDA). RESULTS: LDA model classification accuracy (CA) obtained between IDH-mutant and IDH wild-type PGOs was 90% (91% sensitivity and 89% specificity). Furthermore, 1p/19q codeletion classification within IDH mutant PGOs reached 98% CA (93% sensitivity and 99% specificity), while CDKN2A/B homozygous loss status had 86% CA (63% sensitivity 93% specificity). CONCLUSION: DMS suitability to differentiate IDH-mutated PGOs was thus validated in ex vivo cultured samples, PGOs. Preliminary results regarding 1p/19q codeleted PGOs and CDKN2A/B loss PGOs identification endorse testing in a prospective intraoperative glioma patient cohort. Our results reveal a sample classification set-up that is compatible with real-time intraoperative surgery guidance.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Hermelo I, Haapala I, Mäkelä M, et al. Patient-derived glioma organoids real time identification of IDH mutation, 1p/19q-codeletion and CDKN2A/B homozygous deletion with differential ion mobility spectrometry. J Neurooncol. 2024. PMID: 39578301. doi:10.1007/s11060-024-04891-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。